A Phase 3, Randomized study of Zanubrutinnig (BGB-3111) compared with Ibrutinig in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
BeiGene, Ltd
Start Date
September 13, 2019
End Date
September 14, 2024
Administered By
Duke Cancer Institute
Awarded By
BeiGene, Ltd
Start Date
September 13, 2019
End Date
September 14, 2024